Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Entegris Inc (ENTG) vs McKesson Corporation (MCK) Price & Performance

Entegris IncTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Entegris Inc vs McKesson Corporation — how do they compare? Entegris Inc trades at $135.63 (market cap $21.12B), while McKesson Corporation trades at $827.7 (market cap $93.23B). The key difference: McKesson Corporation is far larger — about 4.4× Entegris Inc's market cap, and McKesson Corporation pays the higher dividend (0.41%). Which is the better fit depends on your goals.

ENTGMCK
Market Cap
$21.12B$93.23B
Sector
TechnologyHealth
52-Week High
$184.00$995.69
52-Week Low
$68.80$659.01
Enterprise Value
$24.44B$97.87B
Dividend Yield
0.29%0.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Entegris Inc

Entegris (ENTG) trades at $140.63, up 3.2% on the day, with a bearish technical signal and premium valuation metrics. The company reported strong Q1 2026 earnings, beating estimates, and maintains a solid cash flow position. Recent news highlights a quarterly dividend declaration and a non-exclusive cross-licensing agreement for EUV lithography technology.

The outlook is mixed: Wall Street analysts maintain a bullish consensus with a $178.40 price target (26.9% upside), citing AI-driven semiconductor demand as a catalyst. However, risks include elevated valuation multiples, competitive pressures in the semiconductor materials sector, and execution challenges in maintaining recent earnings momentum.

McKesson Corporation

McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.

The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.

Returns comparison

Trailing returns across standard periods

About Entegris Inc

Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.

Read more on ENTG

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK